tumorinfiltr
immun
cell
impact
tumor
growth
progress
inhibitori
receptor
suppress
activ
myeloid
cell
lack
pathway
result
reduct
tumor
growth
convers
tumorigen
effect
trigger
also
describ
investig
role
activ
syngen
mous
tumor
model
show
agonist
antibodi
reach
tumor
signific
impact
tumor
growth
minor
effect
infiltr
immun
myeloid
cell
effect
reproduc
use
two
differ
clone
contrast
show
decreas
melanoma
tumor
burden
presenc
either
endogen
tumorexpress
restor
growth
metastat
melanoma
foci
basi
find
conclud
blockad
endogen
ligand
prevent
tumorigen
effect
myeloid
cell
tumor
microenviron
wherea
agonist
effect
tumor
develop
receptor
involv
regul
inflamm
variou
patholog
includ
autoimmun
diseas
infect
cancer
lack
regulatori
pathway
mice
lead
exacerb
autoimmun
diseas
eg
autoimmun
encephalomyel
collageninduc
arthriti
mice
immun
checkpoint
inhibitori
receptor
axi
play
dual
role
balanc
immun
system
microbi
infect
moreov
sever
virus
eg
human
herpesviru
myxoma
viru
orthologu
trigger
endogen
regul
myeloid
cell
function
previous
show
lack
signal
strongli
enhanc
type
interferon
product
viral
clearanc
improv
outcom
plo
one
http
januari
mous
hepat
coronaviru
infect
particularli
femal
mice
ligat
inhibit
signal
tumor
microenviron
domin
immun
cell
play
key
role
tumor
progress
foster
prolifer
surviv
migrat
transform
cell
hand
immun
cell
tumor
microenviron
could
facilit
antitumor
cellular
respons
activ
properli
elev
level
found
multipl
type
cancer
mani
report
suggest
respons
suppress
antitumor
immun
respons
propos
treatment
block
antibodi
might
benefici
patient
cancer
addit
previous
show
absenc
signal
pathway
inhibit
growth
endogen
cancer
cell
even
without
express
tumor
cell
howev
seem
dual
role
cancer
develop
metastasi
highli
aggress
breast
cancer
anim
model
use
agonist
exert
potent
inhibitori
effect
inflammationdriven
carcinogenesi
metastasi
contrast
squamou
cell
carcinoma
enhanc
abil
metastas
moreov
breast
carcinoma
anim
model
overexpress
result
increas
lymph
node
metastasi
find
support
tumorigen
effect
signal
tumor
microenviron
certain
circumst
gene
undergon
rapid
evolut
mice
creat
varieti
inhibitori
activ
receptor
differ
mice
strain
common
laboratori
mous
strain
eg
balbc
one
inhibitori
wherea
express
akr
nod
strain
four
pair
activ
receptor
first
express
balbc
mous
strain
varieti
allel
recapitul
human
sinc
peopl
one
inhibitori
activ
mice
human
activ
receptor
bind
natur
ligand
unknown
specif
agonist
monoclon
antibodi
receptor
describ
detail
akkaya
et
al
wide
use
antimous
trigger
inhibitori
receptor
activ
receptor
wherea
clone
trigger
sinc
express
balbc
mous
strain
use
inhibitori
strain
upon
differ
stimul
macrophag
abl
differenti
variou
subtyp
instruct
tissu
microenviron
tradit
macrophag
divid
two
opposit
phenotyp
classic
altern
activ
cell
respect
classic
activ
macrophag
inhibit
express
cell
divers
tissu
kone
et
al
demonstr
express
human
mous
cell
thu
trigger
provid
immunosuppress
signal
would
contribut
immuneregulatori
capac
macrophag
howev
strategi
may
also
repress
pathway
associ
classic
macrophag
activ
studi
examin
role
pathway
tumor
develop
treatment
agonist
inhibit
tumor
growth
sever
tumor
model
mice
endogen
express
indic
stimul
affect
tumor
growth
thu
investig
effect
defici
system
develop
mous
melanoma
cell
show
express
either
host
tumor
cell
increas
tumor
burden
result
show
consid
therapeut
target
rather
antagonist
agonist
antibodi
use
compani
biocero
bv
play
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
provid
research
materi
antibodi
compet
interest
involv
one
biocero
bv
alter
author
adher
plo
one
polici
share
data
materi
femal
wild
type
wt
balbc
mice
purchas
anim
hous
polish
academi
scienc
mossakowski
medic
research
center
warsaw
poland
wild
type
mice
obtain
univers
medic
center
utrecht
rear
anim
hous
maria
sklodowskacuri
institut
oncolog
warsaw
poland
experi
perform
anim
facil
medic
univers
warsaw
end
experi
mice
sacrif
anesthesia
overdos
studi
none
mice
experienc
unintend
discomfort
requir
intervent
allevi
suffer
vivo
experi
specif
procedur
protocol
use
studi
perform
accord
guidelin
approv
first
local
ethic
committe
anim
experiment
warsaw
mice
tumor
typic
shape
size
start
therapi
exclud
experi
murin
breast
mammari
carcinoma
lewi
lung
carcinoma
llc
melanoma
cell
line
purchas
american
type
cultur
collect
manassa
va
usa
maintain
rpmi
medium
supplement
vv
heatinactiv
fetal
calf
serum
fc
hyclon
antibioticantimycot
solut
sigma
melanoma
cell
stabl
express
firefli
luciferas
gener
transduct
pmxlucneo
express
vector
without
fulllength
mous
cultur
neomycin
select
melanoma
cell
maintain
dmem
supplement
fc
penicillinstreptomycin
mixtur
sigma
superfici
tumor
model
induc
balbc
mice
subcutan
inocul
cell
right
thigh
day
llc
cell
inject
pb
matrigel
growth
factor
reduc
corn
lifesci
usa
mixtur
mice
inject
tail
vein
everi
day
start
day
clone
match
control
antibodi
rat
respect
per
dose
melanoma
without
stabl
express
togeth
luciferas
marker
use
respect
mice
wild
type
control
inject
right
flank
mixtur
cell
pbsmatrigel
mixtur
melanoma
tumor
growth
monitor
vivo
bioluminesc
imag
end
mice
inject
ip
dluciferin
syd
lab
natick
usa
mgkg
min
anesthet
isofluran
visual
use
ivi
imag
system
xenogen
alameda
ca
usa
imag
analyz
live
imag
softwar
packag
calip
life
scienc
hopkinton
usa
quantifi
bioluminesc
bli
signal
mice
region
interest
roi
drawn
tumor
region
result
use
gener
growth
curv
melanoma
bioluminesc
data
present
averag
radianc
photonsseccm
steradian
tumor
cut
small
piec
digest
min
use
collagenas
type
iv
sigma
dnase
sigma
next
tissu
fragment
dissoci
use
gentlemac
dissoci
filter
cell
strainer
wash
pb
contain
mm
edta
fc
centrifug
stain
spleen
forc
cell
strainer
cell
centrifug
necessari
erythrocyt
lyse
use
buffer
contain
mm
nh
cl
mm
nah
co
mm
edta
ph
stain
cell
block
normal
rat
serum
stain
fluoresc
data
analyz
use
graphpad
prism
softwar
statist
signific
calcul
use
studentst
test
mannwhitney
test
appropri
investig
role
therapeut
modul
signal
pathway
tumor
progress
mice
subcutan
inocul
mammari
gland
cancer
cell
treat
agonist
clone
isotyp
control
antibodi
administ
time
iv
dose
everi
third
day
start
day
inocul
tumor
cell
treatment
agonist
signific
effect
growth
tumor
fig
analyz
tumorinfiltr
immun
myeloid
cell
accord
gate
strategi
present
fig
upon
treatment
found
decreas
fraction
tumor
macrophag
simultan
smaller
increas
percentag
cell
fig
intratumor
monocyt
remain
myeloid
cell
affect
agonist
fig
treatment
decreas
fluoresc
flow
cytometri
use
antibodi
clone
detect
fig
analyz
intratumor
immun
cell
popul
prove
tumor
penetr
intraven
administ
similarli
analyz
composit
splenic
myeloid
cell
popul
found
signific
differ
frequenc
cell
fig
express
significantli
decreas
analyz
popul
except
cell
fig
howev
rel
differ
observ
splenocyt
smaller
tumor
subpopul
exclud
possibl
lack
therapeut
effect
agonist
antibodi
due
simultan
trigger
inhibitori
activ
receptor
conduct
experi
agonist
antibodi
clone
balbc
mice
trigger
similarli
intraven
administr
affect
growth
tumor
fig
cytometr
analysi
intratumor
immun
cell
show
effect
clone
myeloid
cell
infiltr
fig
similar
fig
detail
analysi
show
sever
signific
differ
intratumor
cell
popul
upon
treatment
fraction
granulocyt
myeloid
cell
increas
treatment
fig
contrast
monocyt
myeloid
cell
intratumor
macrophag
mhcii
decreas
fig
result
similar
treatment
intratumor
macrophag
also
significantli
decreas
fig
fraction
intratumor
cell
differ
fig
measur
activ
intratumor
lymphocyt
cell
stimul
ex
vivo
pmaionomycin
stain
intracellular
cytokin
product
found
decreas
fig
fig
tumorinfiltr
cell
differ
statist
signific
data
suggest
even
use
clone
specif
inhibitori
signific
effect
tumor
growth
composit
tumorinfiltr
immun
cell
analyz
potenti
therapeut
effect
immunogen
model
analyz
effect
treatment
two
distinct
tumor
model
llc
lewi
lung
carcinoma
melanoma
tumor
model
known
immunogen
syngen
mice
strain
proinflammatori
characterist
found
signific
effect
growth
subcutan
inocul
llc
fig
intraven
inocul
result
mostli
foci
format
lung
fig
sinc
llc
grew
flat
tumor
decid
quantifi
growth
surfac
wherea
growth
monitor
light
emit
luciferas
express
tumor
cell
llc
tumor
observ
differ
percentag
main
myeloid
cell
popul
fig
similarli
lung
tumorbear
mice
differ
percentag
main
myeloid
cell
popul
found
fig
investig
express
observ
signific
decreas
intratumor
myeloid
cell
upon
intraven
treatment
fig
prove
penetr
antibodi
subcutan
llc
tumor
result
suggest
agonist
effect
tumor
growth
wildtyp
mice
endogen
ligand
investig
role
axi
tumor
growth
use
luciferaseexpress
melanoma
cell
inocul
syngen
control
wildtyp
wt
mice
direct
measur
tumor
volum
fig
well
bioluminesc
bli
measur
tumor
fig
reveal
mice
develop
smaller
tumor
compar
control
wt
mice
fig
cell
cell
without
cell
express
inocul
iv
wt
mice
see
whether
tumorexpress
affect
tumor
growth
intraven
inocul
cell
dissemin
lung
organ
growth
monitor
bli
regardless
express
tumor
cell
control
wt
mice
higher
tumor
burden
compar
mice
fig
similarli
subcutan
tumor
model
fig
although
lung
tumor
burden
inocul
cell
compar
wt
mice
neg
tumor
grew
significantli
slower
lung
mice
compar
express
melanoma
fig
result
indic
tumor
develop
acceler
endogen
tumorderiv
express
affect
growth
progress
cancer
howev
precis
mechan
action
clear
lack
express
inhibit
endogen
skin
tumor
develop
addit
express
cancer
cell
correl
poor
patient
prognosi
increas
frequenc
immunosuppress
treg
cell
indic
posit
effect
tumor
growth
inhibit
antitumor
respons
howev
tumorsupport
effect
also
possibl
signal
inhibit
activ
protumor
myeloid
cell
domin
effect
probabl
depend
tumor
immunogen
composit
myeloid
cell
express
tumor
inflamm
diminish
product
cytokin
myeloid
cell
indic
antibodi
suppress
function
myeloid
cell
engag
trigger
agonist
reduc
melanoma
tumor
format
lung
particularli
via
inhibit
myeloid
cell
popul
feasibl
protect
metastat
cancer
cell
surveil
immun
cell
importantli
cancer
cell
use
studi
overexpress
ovalbumin
strong
adjuv
abl
induc
adopt
anticanc
respons
studi
inject
agonist
antibodi
monotherapi
affect
growth
subcutan
tumor
melanoma
breast
lung
carcinoma
syngen
tumor
model
suggest
absenc
immunogen
antigen
eg
ova
agonist
effect
presenc
endogen
use
melanoma
tumor
cell
show
lack
interact
host
inhibit
tumor
growth
cell
express
either
host
melanoma
cell
promot
tumor
cell
growth
howev
trigger
agonist
enhanc
tumor
growth
studi
use
sever
addit
tumor
model
variou
degre
intratumor
inflamm
confirm
mono
treatment
therapeut
effect
without
addit
inflamm
contrast
use
model
colon
carcinoma
recent
shown
treatment
suppress
tumor
growth
modifi
immun
cell
recruit
presenc
inflamm
modul
signal
might
import
treatment
cancer
treatment
agonist
effect
tumor
develop
without
addit
immun
inflammatori
stimul
howev
blockad
interact
could
inhibit
tumor
growth
support
antagonist
antibodi
treatment
option
cancer
case
express
intratumor
immun
cell
could
posit
indic
use
block
antibodi
project
administr
jakub
golab
lind
meyaard
tomasz
p
rygiel
